FDA Approves CAR-T Cell Therapy Brexucabtagene Autoleucel for R/R MCL

On July 24, 2020, Kite, a Gilead Company, announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Read FDA announcement.

Read corporate press release.

Posted 7/24/2020